Patents by Inventor Gopalan Balasubramanian
Gopalan Balasubramanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11180504Abstract: This invention relates to carbapenem compounds of the following formula: wherein A, Z, X, R1, and R4 are as described herein, as well as stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.Type: GrantFiled: March 15, 2017Date of Patent: November 23, 2021Assignees: ORCHID PHARMA LTD., MERCK SHARP & DOHME CORP.Inventors: Gopalan Balasubramanian, Maneesh Paul-Satyaseela, Chidambaram Venkateswaran Srinivasan, Sridhar Ramanathan Iyer, Hariharan Periasamy, Venkatesan Parameswaran, Bharani Thirunavukkarasu, Prabhakar Rao Gunturu, Manjula Devi Deshkumar, Venkateshwarlu Jakkala, Michael Miller, Ravi P. Nargund, Sheo Singh, Shuzhi Dong, Hongwu Wang, Katherine Young
-
Publication number: 20200291029Abstract: This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.Type: ApplicationFiled: March 15, 2017Publication date: September 17, 2020Inventors: Gopalan Balasubramanian, Maneesh Paul-Satyaseela, Chidambaram Venkateswaran Srinivasan, Sridhar Ramanathan Iyer, Hariharan Periasamy, Venkatesan Parameswaran, Bharani Thirunavukkarasu, Prabhakar Rao Gunturu, Manjula Devi Deshkumar, Venkateshwarlu Jakkala, Michael Miller, Ravi P. Nargund, Sheo Singh, Shuzhi Dong, Hongwu Wang, Katherine Young
-
Patent number: 10201532Abstract: Described herein are compounds and their use in the treatment of infections. The compound of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvates, pharmaceutically acceptable salts and pharmaceutical compositions described herein are also useful as ?-lactamase inhibitors, which restore or enhance the antibiotic spectrum of a suitable antibiotic agent. The compounds of formula (I) act as inhibitors of ?-lactamases. These compounds restore/potentiate the activities of ?-lactam antibiotics against carbapenemases. These compounds find use in diagnostic method for detecting ?-lactamases.Type: GrantFiled: November 25, 2011Date of Patent: February 12, 2019Assignee: ALLECRA THERAPEUTICS GMBHInventors: Senthilkumar Udayampalayam Palanisamy, Maneesh Paul-Satyaseela, Shridhar Narayanan, Gopalan Balasubramanian, Aravind Appu, Senthilnathan Manickam, Hariharan Periasamy
-
Patent number: 8828999Abstract: Pyrimidine compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof, are useful are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases and in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever.Type: GrantFiled: February 26, 2013Date of Patent: September 9, 2014Assignee: Orchid Chemicals & Pharmaceuticals LimitedInventors: Ganapavarapu Sharma, Venkatesan Parameswaran, Gopalan Balasubramanian, Santosh Vishwakarma, Sanjeev Saxena
-
Publication number: 20140187594Abstract: Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver; diabetic complications such as macro (ischemic heart disease, cerebrovascular disease and peripheral vascular disease) and micro (cataract, retinopathy nephropathy neuropathy, maculopathy and glaucoma) vascular complication; and cardiovascular diseases such as atherosclerosis, restenosis, hypertension, vasospasm, and cardiac hypertrophy; and lung disorders and lung fibrosis.Type: ApplicationFiled: March 28, 2011Publication date: July 3, 2014Applicant: ORCHID CHEMICALS AND PHARMACEUTICALS LTDInventors: Shridhar Narayanan, Jeyamurugan Mookkan, Jayanarayan Kulathingal, Narayanan Surendran, Gajendra Singh, Gopalan Balasubramanian
-
Publication number: 20140057888Abstract: Described herein are compounds and their use in the treatment of infections. The compound of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvates, pharmaceutically acceptable salts and pharmaceutical compositions described herein are also useful as ?-lactamase inhibitors, which restore or enhance the antibiotic spectrum of a suitable antibiotic agent. The compounds of formula (I) act as inhibitors of ?-lactamases. These compounds restore/potentiate the activities of ?-lactam antibiotics against carbapenemases. These compounds find use in diagnostic method for detecting ?-lactamases.Type: ApplicationFiled: November 25, 2011Publication date: February 27, 2014Inventors: Senthilkumar Udayampalayam Palanisamy, Maneesh Paul-Satyaseela, Shridhar Narayanan, Gopalan Balasubramanian, Aravind Appu, Senthilnathan Manickam, Hariharam Periasamy
-
Patent number: 8580795Abstract: Compounds of the formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, N-oxides, metabolites and prodrugs thereof. These compounds are phosphodiesterase type 4 (PDE4) inhibitors. They are useful in the treatment of a variety of allergic or inflammatory diseases including asthma, COPD, chronic bronchitis, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, uveitis, NASH and lupus.Type: GrantFiled: January 21, 2010Date of Patent: November 12, 2013Assignee: Orchid Chemicals & Pharmaceuticals LimitedInventors: Gopalan Balasubramanian, Sukunath Narayanan, Ganapavarapu Veera Raghava Sharma, Lavanya Andiappan, Shridhar Narayanan, Sanjeev Saxena, Sridharan Rajagopal, Santosh Lolaknath Vishwakarma, Saravanan Thirunavukkarasu
-
Patent number: 8466145Abstract: Described are novel compounds of the Formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol, triglyceride levels; treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis, rheumatoid arthritis; treatment and/or prophylaxis of type II diabetes. These compounds are more particularly dipeptidyl peptidase (DPP IV) inhibitors.Type: GrantFiled: January 7, 2010Date of Patent: June 18, 2013Assignee: Orchid Chemicals & Pharmaceuticals LimitedInventors: Gopalan Balasubramanian, Sukumar Sakamuri, Gajendra Singh, Sivanesan Dharmalingam, Franklin Pooppady Xavier, Shridhar Narayanan, Jeyamurugan Mookkan, Jeganatha Sivakumar Balasubramanian, Agneeswari Rajalingam, Jayanarayan Kulathingal
-
Patent number: 8420653Abstract: Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases.Type: GrantFiled: January 30, 2009Date of Patent: April 16, 2013Assignee: Orchid Chemicals & Pharmaceuticals LimitedInventors: Visweswara Akella Satya Surya Srinivas, Ravikumar Tadiparthi, Ganapavarapu Veera Raghava Sharma, Thirunavukkarasu Sappanimuthu, Durairaj Peter Bhakiaraj, Virendra Kachhadia, Kilambi Narasimhan, Sathya Narayana Thara, Sriram Rajagopal, Sukunath Narayanan, Venkatesan Parameswaran, Venkatesan Janarthanam, Maruthikumar Narayanam, Sathyanarayana Gadde, Uma Ramachandran, Gopalan Balasubramanian, Narayanan Surendran, Shridhar Narayanan, Lolaknath Santosh Vishwakarma, Sanjeev Saxena, Nishikanth Reddy Gaddam
-
Patent number: 8420689Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor.Type: GrantFiled: January 14, 2011Date of Patent: April 16, 2013Assignee: Glenmark Pharmaceuticals S.A.Inventors: Meyyappan Muthuppalaniappan, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan
-
Patent number: 8263648Abstract: The present invention relates to novel heterocyclic compounds that are useful as phosphodiesterase inhibitors (PDEs) in particular phosphodiesterase type 4 (PDE IV) inhibitors and phosphodiesterase type 10 (PDE 10) inhibitors, processes for their preparation, pharmaceutical compositions containing them and their use in treating allergic and inflammatory diseases as well as for inhibiting the production of Tumor Necrosis Factor (TNF-?).Type: GrantFiled: September 10, 2007Date of Patent: September 11, 2012Assignee: Mylan Laboratories Ltd.Inventors: Gopalan Balasubramanian, Ravi Dhamjewar, Shrikant Havale, Sreedhara Swamy Keshavapura Hosamane
-
Publication number: 20120142748Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor.Type: ApplicationFiled: January 14, 2011Publication date: June 7, 2012Applicant: Glenmark Pharmaceuticals S.A.Inventors: Meyyappan MUTHUPPALANIAPPAN, Gopalan BALASUBRAMANIAN, Srinivas GULLAPALLI, Neelima Khairatkar JOSHI, Shridhar Narayanan
-
Publication number: 20110269753Abstract: Compounds of the formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, N-oxides, metabolites and prodrugs thereof. These compounds are phosphodiesterase type 4 (PDE4) inhibitors. They are useful in the treatment of a variety of allergic or inflammatory diseases including asthma, COPD, chronic bronchitis, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, uveitis, NASH and lupus.Type: ApplicationFiled: January 21, 2010Publication date: November 3, 2011Applicant: ORCHID RESEARCH LABORATORIES LTD.Inventors: Gopalan Balasubramanian, Sukunath Narayanan, Ganapavarapu Veera Raghava Sharma, Lavanya Andiappan, Shridhar Narayanan, Sanjeev Saxena, Sridharan Rajagopal, Santosh Lolaknath Vishwakarma, Saravanan Thirunavukkarasu
-
Publication number: 20110257164Abstract: Described are novel compounds of the Formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol, triglyceride levels; treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis, rheumatoid arthritis; treatment and/or prophylaxis of type II diabetes. These compounds are more particularly dipeptidyl peptidase (DPP IV) inhibitors.Type: ApplicationFiled: January 7, 2010Publication date: October 20, 2011Applicant: ORCHID RESEARCH LABORATORIES LIMITEDInventors: Gopalan Balasubramanian, Sukumar Sakamuri, Gajendra Singh, Sivanesan Dharmalingam, Franklin Pooppady Xavier, Shridhar Narayanan, Jeyamurugan Mookkan, Jeganatha Sivakumar Balasubramanian, Agneeswari Rajalingam, Jayanarayan Kulathingal
-
Publication number: 20110212943Abstract: Provided herein are novel bridged cyclic derivatives of the general formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds can inhibit HDACs and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, neurode-generative disorders etc.Type: ApplicationFiled: October 14, 2009Publication date: September 1, 2011Applicant: ORCHID RESEARCH LABORATORIES LIMITEDInventors: Gopalan Balasubramanian, Ponpandian Thanasekaran, Sridharan Rajagopal, Bharathimohan Kuppusamy, Virendra Kachhadia, Vignesh Radhakrishnan, Sivasudar Velaiah, Shridhar Narayanan, Mandar Bhonde, Praveen Rajendran, Sriram Rajagopal
-
Patent number: 7985759Abstract: The present invention relates to novel compounds representated by formula (I), where R, R1, R2, R3, X, Y, m, n are as defined. The present invention relates to compounds of the general formula I their derivatives, their analogs, their tautomeric forms, their stereoisomers, their diastereomers, their bioisosteres, their polymorphs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them which are predominantly dipeptidyl peptidase IV inhibitors. The present invention also relates to the processes for the preparation of novel compounds of formula (I) and their use in treating type II diabetes and diabetic complications thereof and also for treating dislipidemia, hypercholesterolemia, obesity and hyperglycemia.Type: GrantFiled: March 30, 2007Date of Patent: July 26, 2011Assignee: Matrix Laboratories Ltd.Inventors: Gopalan Balasubramanian, Ravi Dhamjewar, Rasheed Mohammed, Sreedhara Swamy Keshavapura Hosamane, Ishtiyaque Ahmad
-
Patent number: 7923465Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenerative disorders, eating disorders, weight loss or control, and obesity).Type: GrantFiled: June 1, 2006Date of Patent: April 12, 2011Assignee: Glenmark Pharmaceuticals S.A.Inventors: Meyyappan Muthuppalaniappan, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan
-
Publication number: 20100329998Abstract: Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases.Type: ApplicationFiled: January 30, 2009Publication date: December 30, 2010Inventors: Visweswara Akella Satya Surya Srinivas, Ravikumar Tadiparthi, Ganapavarapu Veera Raghava Sharma, Thirunavukkarasu Sappanimuthu, Durairaj Peter Bhakiaraj, Virendra Kachhadia, Kilambi Narasimhan, Sathya Narayana Thara, Sriram Rajagopal, Om Gaddam, Nishikanth Reddy Gaddam, Sukunath Narayanan, Venkatesan Parameswaran, Venkatesan Janarthanam, Maruthikumar Narayanam, Sathyanarayana Gadde, Uma Ramachandran, Gopalan Balasubramanian, Narayanan Surendran, Shridhar Narayanan, Lolaknath Santosh Vishwakarma, Sanjeev Saxena
-
Patent number: 7538128Abstract: The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: wherein X, Y, a, R1, and R2 are as defined herein.Type: GrantFiled: February 15, 2007Date of Patent: May 26, 2009Assignee: Glenmark Pharmaceuticals S.A.Inventors: Abraham Thomas, Gopalan Balasubramanian, V. S. Prasadarao Lingam, Daisy Manish Shah
-
Publication number: 20080234259Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).Type: ApplicationFiled: June 1, 2006Publication date: September 25, 2008Applicant: Glenmark Pharmaceuticals S.A.Inventors: Meyyappan Muthuppalaniappan, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan